Eli Lilly and Company (LLY) Shares are Up 1.59%

Eli Lilly and Company (LLY) : Traders are bullish on Eli Lilly and Company (LLY) as it has outperformed the S&P 500 by a wide margin of 1.58% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.66%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.59% in the last 1 week, and is up 4.99% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 3.1% and the 50-Day Moving Average is 7.75%. Eli Lilly and Company is up 10.48% in the last 3-month period. Year-to-Date the stock performance stands at -0.28%.


Eli Lilly and Company (NYSE:LLY): On Fridays trading session , Opening price of the stock was $83.07 with an intraday high of $83.45. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $82.64. However, the stock managed to close at $82.89, a loss of 0.05% for the day. On the previous day, the stock had closed at $82.93. The total traded volume of the day was 3,016,150 shares.

Also, Jefferies maintains its view on Eli Lilly and Company (NYSE:LLY) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies raises the price target from $100 per share to $105 per share on Eli Lilly and Company. The rating by the firm was issued on July 14, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.